These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 21360301)

  • 21. Site-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer's disease therapy.
    Youdim MBH
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):715-721. PubMed ID: 35190910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Aging.
    Kupershmidt L; Youdim MBH
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.
    Youdim MB; Amit T; Bar-Am O; Weinreb O; Yogev-Falach M
    Neurotox Res; 2006 Dec; 10(3-4):181-92. PubMed ID: 17197368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models.
    Amit T; Bar-Am O; Mechlovich D; Kupershmidt L; Youdim MBH; Weinreb O
    Neuropharmacology; 2017 Sep; 123():359-367. PubMed ID: 28571715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice.
    Kupershmidt L; Amit T; Bar-Am O; Youdim MB; Weinreb O
    Mech Ageing Dev; 2012 May; 133(5):267-74. PubMed ID: 22426424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
    Jiang X; Guo J; Lv Y; Yao C; Zhang C; Mi Z; Shi Y; Gu J; Zhou T; Bai R; Xie Y
    Bioorg Med Chem; 2020 Jun; 28(12):115550. PubMed ID: 32503694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis.
    Kupershmidt L; Weinreb O; Amit T; Mandel S; Carri MT; Youdim MB
    FASEB J; 2009 Nov; 23(11):3766-79. PubMed ID: 19638399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of potential anti-AD hybrids with monoamine oxidase B inhibitory and iron-chelating effects.
    Guo J; Mi Z; Jiang X; Zhang C; Guo Z; Li L; Gu J; Zhou T; Bai R; Xie Y
    Bioorg Chem; 2021 Mar; 108():104564. PubMed ID: 33353806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer's disease.
    Liu W; Lang M; Youdim MBH; Amit T; Sun Y; Zhang Z; Wang Y; Weinreb O
    Neuropharmacology; 2016 Oct; 109():376-385. PubMed ID: 27318273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.
    Mandel S; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2007 Aug; 82(6):348-60. PubMed ID: 17659826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
    Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
    Youdim MB; Weinstock M
    Cell Mol Neurobiol; 2001 Dec; 21(6):555-73. PubMed ID: 12043833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators.
    Amit T; Avramovich-Tirosh Y; Youdim MB; Mandel S
    FASEB J; 2008 May; 22(5):1296-305. PubMed ID: 18048580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Curr Drug Targets; 2012 Apr; 13(4):483-94. PubMed ID: 22280345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease.
    Zhang C; Yang K; Yu S; Su J; Yuan S; Han J; Chen Y; Gu J; Zhou T; Bai R; Xie Y
    Eur J Med Chem; 2019 Oct; 180():367-382. PubMed ID: 31325784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
    Mandel S; Weinreb O; Amit T; Youdim MB
    Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain catalase in the streptozotocin-rat model of sporadic Alzheimer's disease treated with the iron chelator-monoamine oxidase inhibitor, M30.
    Sofic E; Salkovic-Petrisic M; Tahirovic I; Sapcanin A; Mandel S; Youdim M; Riederer P
    J Neural Transm (Vienna); 2015 Apr; 122(4):559-64. PubMed ID: 25252744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Additive Neuroprotective Effects of the Multifunctional Iron Chelator M30 with Enriched Diet in a Mouse Model of Amyotrophic Lateral Sclerosis.
    Golko-Perez S; Mandel S; Amit T; Kupershmidt L; Youdim MB; Weinreb O
    Neurotox Res; 2016 Feb; 29(2):208-17. PubMed ID: 26581376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage.
    Mechlovich D; Amit T; Mandel SA; Bar-Am O; Bloch K; Vardi P; Youdim MB
    J Pharmacol Exp Ther; 2010 Jun; 333(3):874-82. PubMed ID: 20237072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.